{"id":"W3181215270","doi":"10.1158/1538-7445.am2021-lb104","title":"Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Adverse effect; Atezolizumab; Internal medicine; Febrile neutropenia; Triple-negative breast cancer; Oncology; Cancer; Gastroenterology; Breast cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262643,0.001226529,0.001827048,0.0005690855,0.0004869934,0.001030172,0.001054464,0.001255943,0.006513551],"category_scores_gemma":[0.0006503025,0.0006159463,0.0009096604,0.0005316548,0.0008129857,0.0008030316,0.0004072547,0.003758759,0.001799642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001606801,"about_ca_system_score_gemma":0.001763089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001652415,"about_ca_topic_score_gemma":0.004396474,"domain_scores_codex":[0.9995412,0.0001890846,0.0000269069,0.00007362902,0.00006351458,0.0001057323],"domain_scores_gemma":[0.9994597,0.00006142324,0.0001069273,0.00004814255,0.00003836144,0.0002854601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5075177,0.1964402,0.01480978,0.0009426827,0.001194436,0.0005866452,0.0002797335,0.00300441,0.148221,0.0003161778,0.008749791,0.1179375],"study_design_scores_gemma":[0.261409,0.712321,0.01347452,0.00003396062,0.0003713254,0.0004729295,0.00005761424,0.000980733,0.006715088,0.0001011784,0.004033414,0.00002921976],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894594,0.001789195,0.0005414511,0.0004753643,0.00009215564,0.002574102,0.001867688,0.0002121033,0.002988559],"genre_scores_gemma":[0.9855748,0.001086907,0.001688546,0.000946411,0.0001313232,0.001872524,0.003940004,0.00004699787,0.004712392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006513551,"threshold_uncertainty_score":0.02179003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04197000312876247,"score_gpt":0.3989249781194998,"score_spread":0.3569549749907373,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}